Through the second week of August, BioWorld has tracked 439 bio/nonprofit deals worth $6.6 billion, with the bulk of that total coming within the last six weeks through the U.S. government purchasing more vaccines and therapies to fight COVID-19.

BioWorld’s Biopharmaceutical Index is at its highest point this year, up 7.85%, showing one of its sharpest rises within the last week. Out of 22 component stocks, 13 are trading above where they were at the end of 2021, as of Aug. 8. This is an improvement from June, when only nine were in such a position.

Biopharma money raised to-date and by month in 2022, including public, private and other financings.

While biopharma M&As fail to keep up with prior years, the dealmaking environment remains strong, as deal values continue to grow. Through early August of this year, biopharma companies have completed 955 deals, including licensings, joint ventures and collaborations, valued at $114.5 billion, which is 7% more than last year ($107 billion) and 2% more than 2020 ($112.2 billion).

The amount of money raised by biopharma companies so far this year is down by 59% in comparison with last year, and there are 42% fewer transactions.